Riliprubart

Summary

Riliprubart (CHEMBL5315038) is a phase-3 clinical-stage antibody; indicated across 6 conditions including guillain-barre syndrome, familial and chronic inflammatory demyelinating polyradiculoneuropathy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 6 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5315038
Name	Riliprubart
Type	Antibody
Max phase	3

Also known as: BIVV-020, BIVV020, Riliprubart, Sar-445088, Sar445088, SAR445088, TNT-020, TNT020, RILIPRUBART

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Guillain-Barre syndrome, familial	3	MONDO:0007691	EFO:0009538
chronic inflammatory demyelinating polyradiculoneuropathy	3	MONDO:0006702	EFO:1000868
autoimmune disease	2	MONDO:0007179	EFO:0005809
autoimmune thrombocytopenic purpura	2	MONDO:0008558	EFO:0007160
autoimmune hemolytic anemia	1	MONDO:0020108	EFO:1001264

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06290128	PHASE3	RECRUITING	A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290141	PHASE3	RECRUITING	A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05156710	PHASE2	ACTIVE_NOT_RECRUITING	BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
NCT04658472	PHASE2	COMPLETED	Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT04669600	PHASE2	COMPLETED	A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)
NCT04269551	PHASE1	COMPLETED	A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease
NCT04802057	PHASE1	TERMINATED	Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).